H.C. Wainwright analyst Joseph Pantginis upgraded Iovanace Biotherapeutics (NASDAQ: IOVA) from Neutral to Buy with a price target of $50.00.The ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE